




Referenze

• TRIAL REGISTRATIVI

- "Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer." New England Journal of Medicine 379.21 (2018): 2027-2039.
- "Brigatinib in crizotinib-refractory ALK+ NSCLC: 2-year follow-up on systemic and intracranial outcomes in the phase 2 ALTA trial." Journal of Thoracic Oncology 15.3 (2020): 404-415.
- The cost-effectiveness of brigatinib in adult patients with ALK inhibitor-naïve ALK-positive non-small cell lung cancer from a US perspective. J Manag Care Spec Pharm. 2022 Sep;28(9):970-979. doi: 10.18553/jmcp.2022.28.9.970. PMID: 36001099; PMCID: PMC10373024.

• ESMO-MCBS

- [https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-for-solid-tumours/esmo-mcbs-scorecards?mcbs_score_cards_form\[searchText\]=brigatinib](https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-for-solid-tumours/esmo-mcbs-scorecards?mcbs_score_cards_form[searchText]=brigatinib)

• EMA

- <https://www.ema.europa.eu/en/medicines/human/EPAR/alunbrig>

• AIFA

- GU Serie Generale n.305 del 09-12-2020 - GU Serie Generale n.266 del 26-10-2020

• REAL WORLD EVIDENCE

- Real-world adherence and persistence with anaplastic lymphoma kinase inhibitors in non-small cell lung cancer. J Manag Care Spec Pharm. 2022 Mar;28(3):305-314. doi: 10.18553/jmcp.2021.21310. Epub 2021 Dec 16. PMID: 34913728.
- Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States. Oncologist. 2022 Sep 2;27(9):790-798. doi: 10.1093/oncolo/oyac116. PMID: 35781589; PMCID: PMC9438904.

• ONGOING TRIALS

- <https://clinicaltrials.gov/search?cond=NSCLC&intr=alectinib&viewType=Table>